Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis

Published:2023-09-11 Issue: Volume: Page:
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Caminati Marco¹^ORCID,Scarpieri Elena²,Maule Matteo³,Pinter Patrick⁴,Schiappoli Michele³,Vaia Rachele³,Senna Gianenrico¹³

Affiliation:

1. Department of Medicine, University of Verona and Verona University Hospital , Verona, Italy

2. School of Specialization in Allergy and Clinical Immunology, Department of Medicine, University of Verona , Verona, Italy

3. Asthma Center and Allergy Unit, Verona University Hospital , Verona, Italy

4. Unit of Otolaryngology, Head and Neck Department, University of Verona , Verona, Italy

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/kead479/51724265/kead479.pdf

Reference9 articles.

1. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis;Wechsler;J Allergy Clin Immunol Pract,2022

2. Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management;Caminati;Expert Rev Respir Med,2022

3. Effect of dupilumab treatment in a severe asthma patient with EGPA;Matucci;J Allergy Clin Immunol Pract,2021

4. Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP;Briegel;J Allergy Clin Immunol Pract,2021

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dupilumab;Reactions Weekly;2024-08-17

2. Biologics in Hypereosinophilic Syndrome and Eosinophilic Granulomatosis with Polyangiitis;Immunology and Allergy Clinics of North America;2024-08

3. Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence;Expert Opinion on Biological Therapy;2024-01-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3